Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study

References

• Ammassari A, Cingolani A, Pezzotti P, De Luca A, Giancola ML, Larocca LM, Antinori A (2000). AIDS-related focal brain lesions in the era of HAART. Neurology 55: 1194–1200.
   PubMedGoogle Scholar
• Andrei G, Snoeck R, Vandeputte M, De Clercq E (1997). Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chem other 41: 587–593.
   PubMed Web of Science ®Google Scholar
• Berenguer J, Miralles P, Arrizabalaga J, Ribera E, Dronda F, Baraia J, Domingo P, Marquez M, Rodriguez -Arrondo FJ, Laguna F, Rubio R, Lopez-Aldeguer J, De Miguel V, and the Gesida 11/99 Study Group (2001). Clinical course and prognostic factors of AIDS-associated pro-gressive multifocal leukoencephalopathy (PML) in pa-tients treated with HAART (GESIDA 11/99). The 8th conference on retroviruses and opportunistic infections, Chicago, February 4–8,2001, Foundation for Retrovirol-ogy and Human Health, p 45, Abstract 10.
   Google Scholar
• Berger JR, Levy RM, Flomenhoft D, Dobbs M (1998). Predic-tive factors for prolonged survival in acquired immun-odeficiency syndrome-as sociate d progre ssive multifoc al leukoencephalopathy. Neurology 44: 341–349.
   Google Scholar
• Blick G, Whiteside M, Griegor P, Hopkins U, Garton T, LaGravinese L (1998). Successful resolution of progres-sive multifocal leukoencephalopathy after combination therapy with cidofovir and cytosine arabinoside. Clin Infect Dis 26: 191–192.
   Google Scholar
• Brambilla AM, Castagna A, Novati R, Cinque P, Terreni MR, Moioli MC, Lazzarin A (1999). Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy. J Neurol 246: 723–725.
   PubMed Web of Science ®Google Scholar
• De Luca A, Ammassari A, Cingolani A, Giancola ML, Antinori A (1998). Disease progression and poor survival of AIDS-associated progressive multifocal leukoencephalopathy despite highly active antiretrovi-ral therapy. AIDS 12: 1937–1938.
   Google Scholar
• De Luca A, Fantoni M, Tartaglione T, Antinori A (1999). Response to cidofovir after failure of highly active antiretroviral therapy alone in a patient with AIDS-as sociate d progre ssive multifocal leukoencephalopathy. Neurology 52: 891–892.
   PubMed Web of Science ®Google Scholar
• De Luca A, Giancola ML, Ammassari A, Grisetti S, Cingolani A, Paglia MG, Govoni A, Murri R, Testa L, d'Arminio Monforte A, Antinori A (2000a). Cido-fovir added to HAART improves virological and clin-ical outcome in AIDS-associated progressive multifocal leukoencephalopathy. AIDS 14: F117–F121.
   Google Scholar
• De Luca A, Giancola ML, Ammassari A, Grisetti S, Paglia MG, Gentile M, Cingolani A, Murri R, Liuzzi G, d'Arminio Monforte A, Antinori A (2000b). The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoen-cephalopathy. /Infect Dis 182: 1077–1083.
   PubMed Web of Science ®Google Scholar
• Dworkin MS, Wan PC, Hanson DL, Jones JL (1999). Progres-sive multifocal leukoencephalopathy: improved sur-vival of human immunodeficiency virus-infected pa-tients in the protease inhibitor era. I Infect Dis 180: 621–625.
   PubMed Web of Science ®Google Scholar
• Gasnault J, Kousignian P, Marchadier E, Karaterki A, DelFraissy JF, Taoufik Y (2001). Cidofovir in AIDS-as sociate d progre ssive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring. I NeuroVirol, submitted.
   Google Scholar
• Houston S, Roberts N, Mashinter L (2001). Failure of cidofovir therapy in progressive multifocal leukoen-cephalopathy unrelated to human immunodeficiency virus. Clin Infect Dis 32: 150–152.
   Google Scholar
• Marra CM, Rajicic N, Barker DE, Cohen B, Clifford D, and the ACTG 363 team (2001). Prospective pilot study of cidofovir for HIV-associated progressive mul-tifocal leukoencephalopathy. The 8th conference on retroviruses and opportunistic infections, February 4–8, 2001, Foundation for Retrovirology and Human Health, p 223, Abstract 596.
   Google Scholar
• Meylan PR, Vuadens P, Mae der P, Sahli R, Tagan MC (1999). Monitoring the response of AIDS-related progressive multifocal leukoencephalopathy to HAART and cido-fovir by PCR for JC virus DNA in the CSF. Eur Neurol 41: 172–174.
   PubMed Web of Science ®Google Scholar
• Miralles P, BerenguerJ, Garcia de Viedma D, Padilla P, Cosin J, Lopez-Bernardo de Quiros JC, Munoz L, Moreno S, Bouza E (1998). Treatment of AIDS-associated progres-sive multifocal leukoencephalopathy with highly active antiretroviral therapy. AIDS 12: 2467–2472.
   PubMed Web of Science ®Google Scholar
• Moore RD, Chaisson RE (1999). Natural history of HIV in-fection in the era of combination antiretroviral therapy. AIDS 13: 1933–1942.
   PubMed Web of Science ®Google Scholar
• Taoufik Y, Gasnault J, Karaterki A, Pierre Ferey M, Marchadier E, Goujard C, Lannuzel A, Delfraissy JF, Dussaix E (1998). Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifo-cal leukoencephalopathy. I Infect Dis 178: 1816–1820.
   PubMed Web of Science ®Google Scholar
• Tassie JM, Gasnault J, Bentata M, Deloumeaux J, Boue F, Billaud E, Costagliola D (1999). Survival improve-ment of AIDS-related progressive multifocal leukoen-cephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. AIDS 13: 1881–1887.
   Google Scholar
• Yiannoutsos C, Major E, Curfman B, Jensen P, Gravell M, Hou J, Clifford D, Hall C (1999). Relation of JC virus DNA in the CSF to survival in AIDS patients with biopsy-proven progressive multifocal leukoen-cephalopathy. Ann Neurol 45: 816–820.
   PubMed Web of Science ®Google Scholar